Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

In terms of valuation, Allakos Inc’s market capitalization stands at $22.69 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.

Earlier this week, Bay Area biotech firm Allakos announced that a key clinical study had flopped and it wouldd be laying off a huge swath of its workforce. Now, those very same woes are hitting ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

Citizens Jmp cut shares of Allakos (NASDAQ:ALLK – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports. Allakos Price Performance NASDAQ ALLK ...

Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...